G
Golimumab [Simponi]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Golimumab
General information
Subsidy Information and Financing Scheme
[MAF] Golimumab (Simponi) Prefilled Syringe 50 mg/0.5 mL, 100 mg/mL
Additional clinical criteria applies
Treatment of adult patients with rheumatoid arthritis
Treatment of adult patients with ankylosing spondylitis
Treatment of adult patients with psoriatic arthritis
Treatment of adult patients with non-radiographic axial spondyloarthritis (axSpA).
Treatment of adult patients with ulcerative colitis
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Golimumab 50 mg/0.5 ml and 100 mg/ml pre-filled syringes in line with their registered indications for treating adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis.
Subsidy status
[R] Golimumab 50mg/0.5ml and 100 mg/ml pre-filled syringes are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[R] Golimumab should be used in line with the clinical criteria in the checklists for MAF applications for anti-TNFα biologics.
[NR] MAF subsidy does not apply to golimumab 12.5mg/1ml concentrate solution for infusion formulation.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Simponi Prefilled Syringe 50 mg/0.5 mL |
|
Simponi Prefilled Syringe 100 mg/mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45ML [SIN16118P]*
SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/1.0 ML (SMARTJECT INJECTOR) [SIN14735P]*
SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 50 MG/0.5 ML (SMARTJECT INJECTOR) [SIN14105P]*
* Clinical information is available for this product.
Intravenous
* Clinical information is available for this product.